hepatitis C

Private Insurers Deny Over Half of All Claims for Hepatitis C Drugs
Private Insurers Deny Over Half of All Claims for Hepatitis C Drugs
Xtalks
hepatitis C
insurers
Flag link:
Balm for Gilead: Unclean Hands Render Patents Unenforceable
Balm for Gilead: Unclean Hands Render Patents Unenforceable
JD Supra
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
The hepatitis C duopoly
The hepatitis C duopoly
Axios
AbbVie
hepatitis C
Gilead Sciences
Flag link:
U.S. court upholds dismissal of $200 million Merck verdict against Gilead
U.S. court upholds dismissal of $200 million Merck verdict against Gilead
Reuters
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
This Small Biotech Is Building on a Surprising Success
This Small Biotech Is Building on a Surprising Success
Motley Fool
AbbVie
Mavyret
Enanta Pharmaceuticals
glecaprevir
hepatitis C
Flag link:
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Xconomy
Conatus Pharmaceuticals
clinical trials
Novartis
emricasan
liver disease
hepatitis C
Flag link:
5 Must-See Quotes From AbbVie's Management
5 Must-See Quotes From AbbVie's Management
Yahoo/Motley Fool
AbbVie
Humira
hepatitis C
Mavyret
Viekira
M&A
Flag link:
Is Gilead Sciences Trying to Put Itself Out of Business?
Is Gilead Sciences Trying to Put Itself Out of Business?
Motley Fool
Gilead Sciences
hepatitis C
HIV
GS-9620
PGT121
Flag link:
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
Motley Fool
drug pricing
Gilead Sciences
AbbVie
hepatitis C
Flag link:
Gilead Sciences' History Points to Future Success
Gilead Sciences' History Points to Future Success
Motley Fool
Gilead Sciences
hepatitis C
NASH
Flag link:
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
What's beyond hepatitis C in the drug launch hit parade? Ibrance and Tecfidera, for two
Fierce Pharma
drug launches
hepatitis C
Ibrance
Tecfidera
Biogen
Pfizer
Gilead Sciences
Flag link:
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Biopharma Dive
Gilead Sciences
Merck
patents
Sovaldi
Harvoni
hepatitis C
Idenix
Flag link:
Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
Reuters
Gilead Sciences
hepatitis C
patents
Merck
Sovaldi
Harvoni
Flag link:
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Fierce Pharma
AbbVie
Mavyret
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Flag link:
NICE nods for AbbVie in hep C and Novartis in lung cancer
NICE nods for AbbVie in hep C and Novartis in lung cancer
Pharma Times
NICE
AbbVie
hepatitis C
Maviret
Novartis
Zykadia
ALK-positive non-small cell lung cancer
Flag link:
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the U.S. price: report
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the U.S. price: report
Fierce Pharma
Gilead Sciences
hepatitis C
Sovaldi
China
drug pricing
Flag link:
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
Motley Fool
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Epclusa
Flag link:
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Motley Fool
Gilead Sciences
hepatitis C
Flag link:
Gilead warns hep C sales could fall further
Gilead warns hep C sales could fall further
BioPharma Dive
Gilead Sciences
earnings
hepatitis C
Flag link:
Merck targets high-risk military veterans for hepatitis C lessons
Merck targets high-risk military veterans for hepatitis C lessons
Fierce Pharma
Merck
hepatitis C
Zepatier
Flag link:

Pages